What is the share price of Suven Life Sciences Ltd (SUVEN) today?
The share price of SUVEN as on 5th December 2025 is ₹169. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Suven Life Sciences Ltd (SUVEN) share?
The past returns of Suven Life Sciences Ltd (SUVEN) share are- Past 1 week: -1.68%
- Past 1 month: -15.89%
- Past 3 months: -18.93%
- Past 6 months: -26.75%
- Past 1 year: 27.85%
- Past 3 years: 171.30%
- Past 5 years: 239.26%
What are the peers or stocks similar to Suven Life Sciences Ltd (SUVEN)?
The peers or stocks similar to Suven Life Sciences Ltd (SUVEN) include:What is the market cap of Suven Life Sciences Ltd (SUVEN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Suven Life Sciences Ltd (SUVEN) is ₹3903.46 Cr as of 5th December 2025.What is the 52 week high and low of Suven Life Sciences Ltd (SUVEN) share?
The 52-week high of Suven Life Sciences Ltd (SUVEN) is ₹299.99 and the 52-week low is ₹102.50.What is the PE and PB ratio of Suven Life Sciences Ltd (SUVEN) stock?
The P/E (price-to-earnings) ratio of Suven Life Sciences Ltd (SUVEN) is -24.28. The P/B (price-to-book) ratio is 35.49.Which sector does Suven Life Sciences Ltd (SUVEN) belong to?
Suven Life Sciences Ltd (SUVEN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Suven Life Sciences Ltd (SUVEN) shares?
You can directly buy Suven Life Sciences Ltd (SUVEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Suven Life Sciences Ltd
SUVEN Share Price
169.001.52% (-2.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SUVEN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SUVEN Performance & Key Metrics
SUVEN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -18.42 | 35.49 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
SUVEN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SUVEN Company Profile
Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
SUVEN Forecast
SUVEN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SUVEN
SUVEN
Income
Balance Sheet
Cash Flow
Annual Normal View
SUVEN Income Statement
SUVEN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 564.62 | 648.53 | 312.92 | 28.45 | 21.23 | 17.16 | 27.99 | 40.28 | 17.56 | 13.10 | ||||||||||
Raw Materials | 154.81 | 176.16 | 79.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.42 | ||||||||||
| Power & Fuel Cost | 31.50 | 33.56 | 19.37 | 1.63 | 0.00 | 0.00 | 0.00 | 0.26 | 0.30 | |||||||||||
| Employee Cost | 52.17 | 61.27 | 36.49 | 17.41 | 18.53 | 21.02 | 18.62 | 18.99 | 20.82 | |||||||||||
| Selling & Administrative Expenses | 124.44 | 117.18 | 136.02 | 107.88 | 73.85 | 109.14 | 118.13 | 117.53 | 148.03 | |||||||||||
| Operating & Other expenses | 51.54 | 38.89 | 28.56 | 3.21 | 1.04 | 3.93 | 2.55 | 2.78 | 3.16 | |||||||||||
EBITDA | 150.16 | 221.47 | 12.86 | -101.68 | -72.19 | -116.93 | -111.31 | -99.28 | -154.75 | -206.32 | ||||||||||
| Depreciation/Amortization | 21.41 | 21.31 | 10.79 | 4.17 | 4.35 | 4.39 | 6.54 | 6.50 | 5.82 | 5.57 | ||||||||||
| PBIT | 128.75 | 200.16 | 2.07 | -105.85 | -76.54 | -121.32 | -117.85 | -105.78 | -160.57 | -211.89 | ||||||||||
| Interest & Other Items | 5.68 | 4.63 | 1.91 | 0.55 | 0.94 | 0.67 | 0.41 | 0.30 | 0.17 | 0.01 | ||||||||||
| PBT | 123.07 | 195.53 | 0.16 | -106.40 | -77.48 | -121.99 | -118.26 | -106.08 | -160.74 | -211.90 | ||||||||||
| Taxes & Other Items | 35.88 | 71.84 | 24.06 | -12.18 | -5.32 | 0.00 | 0.00 | -1.00 | 0.00 | — | ||||||||||
| Net Income | 87.19 | 123.69 | -23.90 | -94.22 | -72.16 | -121.99 | -118.26 | -105.08 | -160.74 | -211.90 | ||||||||||
| EPS | 0.32 | 0.45 | -0.09 | -0.65 | -5.22 | -8.25 | -6.29 | -4.82 | -7.37 | -9.72 | ||||||||||
| DPS | 0.05 | 0.07 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.15 | 0.15 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SUVEN Company Updates
SUVEN Stock Peers
SUVEN Past Performance & Peer Comparison
SUVEN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Suven Life Sciences Ltd | -24.28 | 35.49 | — |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
SUVEN Stock Price Comparison
Compare SUVEN with any stock or ETFCompare SUVEN with any stock or ETF
SUVEN
SUVEN Holdings
SUVEN Shareholdings
SUVEN Promoter Holdings Trend
SUVEN Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 2.90%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SUVEN Institutional Holdings Trend
SUVEN Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.06%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUVEN Shareholding Pattern
SUVEN Shareholding Pattern
SUVEN Shareholding History
SUVEN Shareholding History
Foreign Institutions
Mutual Funds Invested in SUVEN
Mutual Funds Invested in SUVEN
No mutual funds holding trends are available
Top 2 Mutual Funds holding Suven Life Sciences Ltd
| Funds (Top 2) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.09% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 83/124 (-13) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0001% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 888/1023 (-150) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SUVEN stock
smallcases containing SUVEN stock
Looks like this stock is not in any smallcase yet.
SUVEN Events
SUVEN Events
SUVEN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUVEN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SUVEN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUVEN has not given any dividends in last 5 years
SUVEN Upcoming Dividends
SUVEN Upcoming Dividends
No upcoming dividends are available
SUVEN Past Dividends
SUVEN Past Dividends
Cash Dividend
Ex DateEx DateFeb 17, 2021
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateFeb 14, 2019
Interim
Interim | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Feb 14, 2019
Cash Dividend
Ex DateEx DateFeb 6, 2018
Interim
Interim | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Feb 6, 2018
Cash Dividend
Ex DateEx DateFeb 8, 2017
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 8, 2017
Cash Dividend
Ex DateEx DateMar 14, 2016
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Mar 14, 2016
SUVEN Stock News & Opinions
SUVEN Stock News & Opinions
Articles & Videos
Earnings
Suven Life Sciences reports consolidated net loss of Rs 77.31 crore in the September 2025 quarter
Net Loss of Suven Life Sciences reported to Rs 77.31 crore in the quarter ended September 2025 as against net loss of Rs 49.64 crore during the previous quarter ended September 2024. Sales declined 64.20% to Rs 0.92 crore in the quarter ended September 2025 as against Rs 2.57 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales0.922.57 -64 OPM %-8670.65-2031.52 - PBDT-75.99-48.19 -58 PBT-77.31-49.64 -56 NP-77.31-49.64 -56 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Suven Life Sciences announces board meeting date
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Suven Life Sciences reports consolidated net loss of Rs 51.52 crore in the June 2025 quarter
Net Loss of Suven Life Sciences reported to Rs 51.52 crore in the quarter ended June 2025 as against net loss of Rs 28.04 crore during the previous quarter ended June 2024. Sales rose 85.15% to Rs 1.87 crore in the quarter ended June 2025 as against Rs 1.01 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1.871.01 85 OPM %-2713.90-3023.76 - PBDT-50.15-26.55 -89 PBT-51.52-28.04 -84 NP-51.52-28.04 -84 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Suven Life Sciences to conduct board meeting
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Suven Life Sciences updates on Phase-2b clinical trial of Ropanicant
Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD). The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery 'sberg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase 2b trial being conducted in exclusively in USA under FDA IND. Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD.' said Venkat Jasti, Chairman and MD of Suven Life Sciences.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Suven Life Sciences Ltd Slides 3.06%, BSE Healthcare index Shed 1.34%
Suven Life Sciences Ltd fell 3.06% today to trade at Rs 220. The BSE Healthcare index is down 1.34% to quote at 42505.21. The index is down 0.02 % over last one month. Among the other constituents of the index, Syncom Formulations (India) Ltd decreased 2.97% and Concord Biotech Ltd lost 2.72% on the day. The BSE Healthcare index went up 15.59 % over last one year compared to the 5.82% surge in benchmark SENSEX. Suven Life Sciences Ltd has added 6% over last one month compared to 0.02% fall in BSE Healthcare index and 0.02% drop in the SENSEX. On the BSE, 155 shares were traded in the counter so far compared with average daily volumes of 1.08 lakh shares in the past one month. The stock hit a record high of Rs 272 on 12 Jun 2025. The stock hit a 52-week low of Rs 97.03 on 20 Jun 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Suven Life Sciences schedules EGM
Suven Life Sciences announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 5 June 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Suven Life Sciences to conduct AGM
Suven Life Sciences announced that the 36th Annual General Meeting(AGM) of the company will be held on 22 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Suven Life Sciences reports consolidated net loss of Rs 43.94 crore in the March 2025 quarter
Net Loss of Suven Life Sciences reported to Rs 43.94 crore in the quarter ended March 2025 as against net loss of Rs 26.54 crore during the previous quarter ended March 2024. Sales declined 38.49% to Rs 1.47 crore in the quarter ended March 2025 as against Rs 2.39 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 160.75 crore in the year ended March 2025 as against net loss of Rs 105.08 crore during the previous year ended March 2024. Sales declined 43.03% to Rs 6.66 crore in the year ended March 2025 as against Rs 11.69 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1.472.39 -38 6.6611.69 -43 OPM %-2980.95-1266.95 --2489.19-1095.04 - PBDT-42.60-26.03 -64 -154.92-107.04 -45 PBT-43.94-27.54 -60 -160.75-113.54 -42 NP-43.94-26.54 -66 -160.75-105.08 -53 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Suven Life Sciences to declare Quarterly Results
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -9.2%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 0.01% to 0%